Published on:

From the early 1950s to the later 1980s, the Marine Corps base at Camp Lejeune in North Carolina provided residents and employees with drinking water that was heavily contaminated with toxic chemicals. Extensive scientific research has revealed that the poisoned water supply at Camp Lejeune had a devastating impact on the long-term health of base residents, who have suffered significantly higher rates of birth defects, cancer, and neurological conditions.

Many of the Camp Lejeune water contamination victims have brought civil lawsuits seeking financial settlements for their injuries. Unfortunately, a harsh law in North Carolina called a statute of repose has effectively blocked all of these victims from pursuing their claims and getting the justice they deserve. However, the U.S. Congress has now fixed this injustice by passing a new federal law that will allow former Lejeune residents to file water contamination lawsuits despite the law in North Carolina.

May 2023 Update

Published on:

Aqueous film-forming foam (AFFF) is a firefighting foam utilized to extinguish flammable liquid pool fires. AFFF contains perfluoroalkyl and poly-fluoroalkyl substances (PFAS), man-made chemicals that are known for their water and stain-resistant properties. PFAS persist in the environment and accumulate in the human body, leading to growing concerns about potential health risks, including cancer, thyroid disease, and reproductive problems. Firefighters face particular risks due to AFFF exposure during firefighting operations.

The History of AFFF

The history of AFFF can be traced back to the development of synthetic foam concentrates during World War II. After the war, researchers began looking for ways to improve firefighting capabilities for aircraft and fuel fires. In 1962, the U.S. Naval Research Laboratory (NRL) started working on developing AFFF. By 1966, the NRL had successfully developed the first AFFF formulation, which was introduced into the market by 3M under the brand name “Light Water.”

Published on:

Roche recently unveiled results from a Phase 3 trial of Tecentriq for early-stage liver cancer. The study looked at the use of  Tecentriq and Avastin.  These two drugs work together to target and destroy cancer cells in the body. Tecentriq strengthens the immune system to fight cancer cells, while Avastin prevents the growth of new blood vessels that supply the tumor with nutrients to grow. The manufacturer of both drugs, Genentech, has indicated that the combination appears to reduce the risk of liver cancer recurrence.

The Tecentriq and Avastin combination reduced the risk of disease recurrence or death by 28% when compared to active surveillance after surgery. These results were presented at the American Association for Cancer Research’s 2023 annual meeting are wildly encouraging and wildly concerning – all at the same time.

Early Stage Liver Cancer

Published on:

The surgical implant manufacturer Exactech recently announced a recall of all its Optetrak® implant systems used in total knee replacement surgeries since 2004. The recall came after the company discovered that a problem with the product packaging was causing the polyethylene insert component in the Optetrak implants to degrade not function properly. This defect is causing the Optetrak knee implant systems to prematurely fail which ultimately requires patients to undergo additional revision surgery.

Individuals who had the Optetrak system implanted and suffered premature failure due to this defect can file a product liability lawsuit against Exactech and potentially recover financial compensation for their pain and medical bills. Our firm is currently accepting Optetrak implant failure cases from patients who suffered a premature failure to their knee replacement implant and had to undergo revision surgery.

Opterak Exactech Recall Lawsuit –  April 2023 Update

Published on:

Recent studies have established that prolonged use or exposure to the industrial herbicide paraquat (Grameoxone) can lead to the development of early-onset Parkinson’s disease. Now thousands of agriculture workers are filing paraquat lawsuits alleging that they developed Parkinson’s due to occupational exposure to paraquat.

The paraquat cases have been consolidated into a “class action” MDL which should eventually results in a global settlement with payments to all claimants. This post will look at how much settlement compensation paraquat plaintiffs might reasonably expect to get.


Related Paraquat Posts

Published on:

Thousands of CPAP machine lawsuits have been filed since medical device company Philips recalled millions of sleep apnea machines after discovering that they were causing users to inhale toxic foam particles.  Our CPAP lawyers are handling these lawsuits in all 50 states.

Thousands of CPAP Lawsuits

Thousands of additional CPAP recall lawsuits have been filed on registered against Philips in the class-action MDL lawsuit.

Published on:

Sprue-like enteropathy is an intestinal condition involving chronic diarrhea, nausea, stomach severe stomach discomfort, and rapid weight loss.

Sprue-like enteropathy is a condition that affects the small intestine and can lead to malnutrition, chronic diarrhea, and weight loss. It has been associated with the use of certain drugs, such as the blood pressure medication olmesartan.

Sprue-Like Enteropathy

Published on:

Warfarin is an anticoagulant medication commonly used to prevent blood clots and stroke in individuals with certain medical conditions such as atrial fibrillation, heart valve replacement, and deep vein thrombosis. It works by blocking the production of certain clotting factors in the blood. Warfarin is one of the most widely prescribed anticoagulants and has been in use for over 60 years.

This page looks at Warfarin side effects and litigation that has surrounded this medication.

Published on:

Eliquis, also known by its generic name apixaban, is an anticoagulant medication prescribed to reduce the risk of stroke and blood clots in patients with nonvalvular atrial fibrillation, as well as to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE).

This post talks about Eliquis side effects. Every drug has them.  But Eliquis has proven to be generally safe and effective.

Our law firm is not involved in any Eliquis lawsuits and attorneys do not believe there are viable causes of action with respect to the side effects of Eliquis.

Published on:

The Bair Hugger warming device has been a popular medical device used in hospitals for years. It is used to keep patients warm during surgeries, which helps prevent hypothermia and other complications. However, studies have suggested that the use of Bair Hugger warming devices during joint replacement surgery may increase the risk of infection.  These studies spawned thousands of lawsuits that evolved into the Bair Hugger class action lawsuit.

What Is the Bair Hugger Warming Device?

The Bair Hugger warming device is a forced-air warming system that was first introduced in 1987. It is a portable device that blows warm air through a disposable blanket, which covers the patient during surgery. The device is designed to maintain the patient’s body temperature, which helps reduce the risk of hypothermia and other complications.

The Bair Hugger was created in the 1980s by Augustine Medical, Inc., which was later acquired by Defendant Arizant Healthcare, Inc. In 2010, Defendant 3M Company purchased Arizant, including the Bair Hugger product line. The Bair Hugger is designed to keep patients warm during surgical procedures by blowing warm, forced air over the patient. It consists of a portable forced-air temperature management unit and a disposable Bair Hugger forced-air blanket, with 25 different styles available that vary in size and coverage, including partial or full coverage of the patient’s body, and some are used underneath the patient. The manufacturer markets Bair Huggers as a warming solution that can be used for various patients, from pediatric to geriatric, and for both short and long procedures. The marketing slogan for Bair Huggers is “Everyone Deserves a Hugg™,” emphasizing its suitability for everyone.